Want to join the conversation?
Pharmaceutical company $PFE announced top-line results from its OPAL Broaden trial, the first Phase 3 study investigating tofacitinib for treating psoriatic arthritis. OPAL Broaden met its primary efficacy endpoints, showing that both tofacitinib 5 mg BID and 10 mg BID were superior to treatment with placebo at 3 months.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.